Neslihan ÜLGER ÖZTÜRK
(İzmir Katip Çelebi Üniversitesi, Beslenme ve Diyetetik Bölümü, İzmir, Türkiye)
Reyhan NERGİZ-UNAL
(Hacettepe Üniversitesi, Beslenme ve Diyetetik Bölümü, Ankara, Türkiye)
Yıl: 2018Cilt: 27Sayı: 1ISSN: 1300-7718Sayfa Aralığı: 14 - 25Türkçe

17 0
Kronik Böbrek Hastalığında Renal İnflamasyon ve Bazı Güncel Diyet Bileşenleri İlişkisi
Kronik böbrek hastalığı, glomerüler filtrasyonun azalmasıyla böbrekte sıvı-solüt dengesinin düzenlenmesi ve metabolik-endokrin fonksiyonlarda kronik ve ilerleyici bozulma hali olarak tanımlanabilir. Kronik böbrek hastalığı gelişiminde rol alan inflamasyon, kronik böbrek hastalığının sonucu olarak da ortaya çıkabilmekte ve KBH varlığına bağlı mortalite artışının en önemli nedenlerinden biri olarak kabul edilmektedir. İnflamasyon ve diyet etkileşimi ile ilgili yapılan güncel araştırmalar çoklu doymamış yağ asitleri, D vitamini, E vitamini gibi besin ögeleri ile karnitin, lipoik asit, flavanoidler, probiyotikler ve prebiyotikler gibi diğer diyet bileşenlerinin renal inflamasyon sürecindeki olumlu etkilerine işaret etmektedir. Derlemede, olası anti-inflamatuvar bazı diyet bileşenlerinin kronik böbrek hastalığı ile ilişkili inflamasyon üzerine etkileri incelenmiştir.
Fen > Tıp > Cerrahi
DergiAraştırma MakalesiErişime Açık
  • Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR: Global prevalence of chronic kidney disease - A systematic review and meta-analysis. PLoS ONE 2016;11:e0158765
  • 2. Suleymanlar G, Utas C, Arinsoy T, Ates K, Altun B, Altiparmak MR, Ecder T, Yilmaz ME, Camsari T, Basci A, Odabas AR, Serdengecti K: A population-based survey of Chronic Renal Disease In Turkey-the CREDIT study. Nephrol Dial Transplant 2011;26:1862-1871
  • 3. Neugarten J, Reckelhoff JF: Gender issues in chronic kidney disease. In: Chronic Renal Disease. San Diego: Academic Press, 2015;69-80
  • 4. Remuzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I, Liu ZH, Miyata T, Perico N, Rodriguez-Iturbe B, Antiga L, Schaefer F, Schieppati A, Schrier RW, Tonelli M: Kidney failure: Aims for the next 10 years and barriers to success. Lancet 2013;382:353-362
  • 5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128
  • 6. Sampaio-Maia B, Simões-Silva L, Pestana M, Araujo R, SoaresSilva IJ: The role of the gut microbiome on chronic kidney disease. In: Sima S, Geoffrey Michael G (eds), Advances in Applied Microbiology. London: Academic Press, 2016;65-94
  • 7. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007;20:440-451
  • 8. Hung KC, Wu CC, Chen HS, Ma WY, Tseng CF, Yang LK, Hsieh HL, Lu KC: Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis. Nephrol Dial Transplant 2011;26:658-664
  • 9. Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M, Appel LJ, Feldman HI, Go AS, He J, Kusek JW, Lash JP, Ojo A, Townsend RR: Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 2017;91:711-719
  • Kumar V, Abbas AK, Aster JC: Robbins Basic Pathology (9nd ed). Philadelphia: Elsevier Health Sciences,2013;472-489
  • 11. Felizardo RJF, Castoldi A, Andrade-Oliveira V, Camara NOS: The microbiota and chronic kidney diseases: A double-edged sword. Clin Trans Immunol 2016;5:e86
  • 12. National Kidney Foundation: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. National Kidney Foundation [İnternet yayını]. 2002 [atıf 20.01.2017]. Erişim: https://www.kidney.org/sites/default/ files/docs/ckd_evaluation_classification_stratification.pdf
  • 13. Abboud O, Adler S, Bertram K, Garabed E, Norbert L, Wheeler D: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. KDİGO [İnternet Yayını]. 2012 [atıf 12.07.2017]; 3: 5-127. Erişim: http://www.kdigo.org/clinical_ practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf
  • 14. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D: Gut microbiome in chronic kidney disease: Challenges and opportunities. Transl Res 2016;179:24-37
  • 15. Evans PD, Taal MW: Epidemiology and causes of chronic kidney disease. Medicine 2015;39:402-406
  • 16. Liu WC, Zheng CM, Lu CL, Lin YF, Shyu JF, Wu CC, Lu KC: Vitamin D and immune function in chronic kidney disease. Clin Chim Acta 2015;450:135-144
  • 17. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J: Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004;65:1031-1040
  • 18. Carrero JJ, Stenvinkel P: Inflammation in Chronic Kidney Disease A2 - Kopple, Joel D. In: Massry SG, Kalantar-Zadeh K (eds), Nutritional Management of Renal Disease. (3rd ed). London: Academic Press, 2013;79-91
  • 19. Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, Coresh J, Klein R: Markers of inflammation predict the long-term risk of developing chronic kidney disease: A population-based cohort study. Kidney Int 2011;80:1231-1238
  • 20. Silverstein DM: Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol 2009;24:1445-1452
  • 21. Sreedhar R, Watanabe K, Arumugam S: General Mechanisms of Immunity and Inflammation. In: Japanese Kampo Medicines for the Treatment of Common Diseases: Focus on Inflammation. Academic Press, 2017; 23-31
  • 22. Neff K, Le Roux C: Chronic kidney disease and inflammation. In: Immunonutrition. New York: CRC Press 2014; 167-180
  • 23. Franceschi C, Campisi J: Chronic Inflammation (Inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014;69:4-9
  • 24. Levy BD, Serhan CN: Resolution and regulation of inflammation. In: Mitchell RN (ed), Pathobiology of Human Disease. San Diego: Academic Press, 2014;332-348
  • 25. Fleit HB: Chronic Inflammation. In: Mitchell RN (ed), Pathobiology of Human Disease. San Diego: Academic Press, 2014; 300-314
  • 26. Kovesdy CP, Kalantar-Zadeh K: Inflammation in chronic kidney disease. In: Sayegh MH (ed), Chronic Kidney Disease, Dialysis, and Transplantation. (3rd ed). Philadelphia: WB Saunders, 2010; 183-197
  • 27. Pahl MV, Vaziri ND: Immune function in chronic kidney disease. In: Chronic Renal Disease. San Diego: Academic Press, 2015; 285-297
  • 28. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-1016
  • 29. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: How can we treat it? Blood Purif 2008;26:291-299
  • 30. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92
  • 31. Keller C, Katz R, Cushman M, Fried LF, Shlipak M: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the MultiEthnic Study of Atherosclerosis (MESA). BMC Nephrol 2008;9:9
  • 32. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O’Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, Benjamin EJ, Fox CS: Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011;26:920-926
  • 33. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS: Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012;7:1938-1946
  • 34. Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, Yamamoto H, Gallagher M, Port FK, Robinson BM: C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2452-2461
  • 35. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, PecoitsFilho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-148
  • 36. Shivappa N, Hebert JR, Rietzschel ER, De Buyzere ML, Langlois M, Debruyne E, Marcos A, Huybrechts I: Associations between dietary inflammatory index and inflammatory markers in the Asklepios Study. Br J Nutr 2015;113:665-671
  • 37. Cavicchia PP, Steck SE, Hurley TG, Hussey JR, Ma Y, Ockene IS, Hebert JR: A new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive protein. J Nutr 2009;139:2365-2372
  • 38. Leavy O: Immune regulation: Brain-fat axis in adaptive immunity. Nat Rev Immunol 2015;15:267 39. Kim MS, Yan J, Wu W, Zhang G, Zhang Y, Cai D: Rapid linkage of innate immunological signals to adaptive immunity by the brain-fat axis. Nat Immunol 2015;16:525-533
  • 40. Harbige LS: Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc 1998;57:555-562
  • 41. Calder PC, Grimble RF: Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 2002;56:14-19
  • 42. Calder PC: n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505-1519
  • 43. Gopinath B, Harris DC, Flood VM, Burlutsky G, Mitchell P: Consumption of long-chain n-3 PUFA, alpha-linolenic acid and fish is associated with the prevalence of chronic kidney disease. Br J Nutr 2011;105:1361-1368
  • 44. Lauretani F, Semba RD, Bandinelli S, Miller ER, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L: Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 2008;54:475-481
  • 45. Priante G, Musacchio E, Valvason C, Baggio B: EPA and DHA suppress AngII- and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. J Nephrol 2009;22:137-143
  • 46. Priante G, Musacchio E, Valvason C, Clari G, Bordin L, Sartori L, Baggio B: Further insights about the beneficial effects of n-3 fatty acids in the early molecular events of renal fibrosis in vitro. J Nephrol 2013;26:652-659
  • 47. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D: Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 2007;29:321-329
  • 48. Sabbatini M, Apicella L, Cataldi M, Maresca I, Nastasi A, Vitale S, Memoli B, Postiglione L, Riccio E, Gallo R, Federico S, Guida B: Effects of a diet rich in N-3 polyunsaturated fatty acids on systemic inflammation in renal transplant recipients. J Am Coll Nutr 2013;32:375-383
  • 49. Peake JM, Gobe GC, Fassett RG, Coombes JS: The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats. Mol Nutr Food Res 2011;55:400-410
  • 50. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, Ristic-Medic DK: Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton) 2007;12:331-336
  • 51. Naini AE, Asiabi RE, Keivandarian N, Moeinzadeh F: Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. Adv Biomed Res 2015;4:167-174
  • 52. Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, Moorhead JF, Varghese Z: EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a PPARgamma-dependent mechanism. Kidney Int 2005;67:867-874
  • 53. Santoro D, Caccamo D, Gagliostro G, Ientile R, Benvenga S, Bellinghieri G, Savica V: Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients. J Nephrol 2013;26:636-644
  • 54. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013
  • 55. Bakdash G, van Capel TMM, Mason LMK, Kapsenberg ML, de Jong EC: Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10- producing T cells. Vaccine 2014;32:6294-6302
  • 56. Yadav AK, Banerjee D, Lal A, Jha V: Vitamin D deficiency, CD4+CD28null cells and accelerated atherosclerosis in chronic kidney disease. Nephrology (Carlton) 2012;17:575-581
  • 57. Alvarez JA, Zughaier SM, Law J, Hao L, Wasse H, Ziegler TR, Tangpricha V: Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 2013;67:264-269
  • 58. Xu S, Chen YH, Tan ZX, Xie DD, Zhang C, Xia MZ, Wang H, Zhao H, Xu DX, Yu DX: Vitamin D3 pretreatment alleviates renal oxidative stress in lipopolysaccharide-induced acute kidney injury. J Steroid Biochem Mol Biol 2015;152:133-141
  • 59. Meireles MS, Kamimura MA, Dalboni MA, Giffoni de Carvalho JT, Aoike DT, Cuppari L: Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: A randomized controlled trial. Clinical Nutrition 2016;35:1251-1258
  • 60. Aggarwal BB, Sundaram C, Prasad S, Kannappan R: Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases. Biochem Pharmacol 2010;80:1613-1631
  • 61. Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D: New strategy of alpha- and gamma-tocopherol to prevent contrastinduced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrol Dial Transplant 2013;28:337-344
  • 62. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebocontrolled trial. Lancet 2000;356:1213-1218
  • 63. Daud ZA, Tubie B, Sheyman M, Osia R, Adams J, Tubie S, Khosla P: Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients. Vasc Health Risk Manag 2013;9:747-761
  • 64. Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG: Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 2003;38:813-819
  • 65. Maniglia FP, Alberto dos Santos RM, Cardeal da Costa JA: The role of nutrition and supplementation in dialysis patient health. In: Dokken BB (ed), Glucose Intake and Utilization in Pre-Diabetes and Diabetes. Boston: Academic Press, 2015;341-347
  • 66. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, Phinney S, Miller G: Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003;64:978-991
  • 67. Salama AF, Kasem SM, Tousson E, Elsisy MKH: Protective role of L-carnitine and vitamin E on the kidney of atherosclerotic rats. Biomedicine & Aging Pathology 2012;2:212-215
  • 68. Lee B-J, Lin J-S, Lin Y-C, Lin P-T: Antiinflammatory effects of l-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition 2015;31:475-479
  • 69. Khalatbari-Soltani S, Tabibi H: Inflammation and l-carnitine therapy in hemodialysis patients: A review. Clin Exp Nephrol 2015;19:331-335
  • 70. Xiang Y, Piao SG, Zou HB, Jin J, Fang MR, Lei DM, Gao BH, Yang CW, Li C: L-Carnitine protects against cyclosporineinduced pancreatic and renal injury in rats. Transplant Proc 2013;45:3127-3134
  • 71. Bellinghieri G, Santoro D, Calvani M, Savica V: Role of carnitine in modulating acute-phase protein synthesis in hemodialysis patients. J Ren Nutr 2005;15:13-17
  • 72. Chen Y, Abbate M, Tang L, Cai G, Gong Z, Wei R, Zhou J, Chen X: L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: A systematic review and meta-analysis. Am J Clin Nutr 2014;99:408-422
  • 73. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arévalo M, Mate A, Vázquez CM: L-Carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. Am J Hypertens 2014;27:460-470
  • 74. Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, Bellinghieri G, Kopple JD: L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients J Ren Nutr 2005;15:225- 230
  • 75. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D: Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006;21:3211-3214
  • 76. Suchitra MM, Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, Sivakumar V, Rao PV: The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2011;22:1155-1159
  • 77. Shakeri A, Tabibi H, Hedayati M: Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 2010;14:498-504
  • 78. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM: Alphalipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009;1790:1149- 1160
  • 79. Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, Farrag MMY: The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology 2008;243:261-270
  • 80. Ramos LF, Kane J, McMonagle E, Le P, Wu P, Shintani A, Ikizler TA, Himmelfarb J: Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Ren Nutr 2011;21:211- 218
  • 81. Khabbazi T, Mahdavi R, Safa J, Pour-Abdollahi P: Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J Ren Nutr 2012;22:244-250
  • 82. Winiarska K, Malinska D, Szymanski K, Dudziak M, Bryla J: Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits. Biochimie 2008;90:450-459
  • 83. Lee KA, Lee YJ, Ban JO, Lee YJ, Lee SH, Cho MK, Nam HS, Hong JT, Shim JH: The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1. Int J Mol Med 2012;30:21-27
  • 84. Bae EH, Lee J, Ma SK, Kim IJ, Frokiaer J, Nielsen S, Kim SY, Kim SW: Alpha-Lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 2009;24:2692- 2700
  • 85. Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W: Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 2009;24:3012-3020
  • 86. Zhang H, Tsao R: Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. Current Opinion in Food Science 2016;8:33-42
  • 87. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA: Positive effect of dietary soy in ESRD patients with systemic inflammation- -correlation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol Dial Transplant 2006;21:2239- 2246
  • 88. Shema-Didi L, Sela S, Ore L, Shapiro G, Geron R, Moshe G, Kristal B: One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: A randomized placebo-controlled trial. Free Radic Biol Med 2012;53:297-304
  • 89. Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gomez-Coronado D, Ortuno J, Lasuncion MA: Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 2006;84:252-262
  • 90. Palanisamy N, Kannappan S, Anuradha CV: Genistein modulates NF-κB-associated renal inflammation, fibrosis and podocyte abnormalities in fructose-fed rats. Eur J Pharmacol 2011;667:355- 364
  • 91. Prince PD, Lanzi CR, Toblli JE, Elesgaray R, Oteiza PI, Fraga CG, Galleano M: Dietary (-)-epicatechin mitigates oxidative stress, NO metabolism alterations, and inflammation in renal cortex from fructose-fed rats. Free Radic Biol Med 2016;90:35-46
  • 92. Diwan V, Brown L, Gobe GC: The flavonoid rutin improves kidney and heart structure and function in an adenine-induced rat model of chronic kidney disease. Journal of Functional Foods 2017;33:85-93
  • 93. Sahu BD, Kuncha M, Sindhura GJ, Sistla R: Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 2013;20: 453-460
  • 94. FAO/WHO Working Group: Guidelines for the Evaluation of Probiotics in Food. FAO/WHO [İnternet yayını]. 2002 [atıf 22.02.2017]. Erişim: http://www.who.int/foodsafety/fs_ management/en/probiotic_guidelines.pdf
  • 95. Gibson GR: Fibre and effects on probiotics (the prebiotic concept). Clinical Nutrition Supplements 2004;1:25-31 96. Maslowski KM, Mackay CR: Diet, gut microbiota and immune responses. Nat Immunol 2011;12:5-9
  • 97. Frei R, Akdis M, O’Mahony L: Prebiotics, probiotics, synbiotics, and the immune system: Experimental data and clinical evidence. Curr Opin Gastroenterol 2015;31:153-158
  • 98. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A: The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013;17:323-333
  • 99. Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F: Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review. Journal of Functional Foods 2016;25:511-522
  • 100. Zirker L: Probiotic use in chronic kidney disease patients. J Ren Nutr 2014;24:47-49
  • 101. Hatch M, Vaziri ND: Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci (Lond) 1994;86:511-516
  • 102. Rossi M, Klein K, Johnson DW, Campbell KL: Pre-,pro-, and synbiotics: Do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol 2012;2012:673631
  • 103. Huang W, Zhou L, Guo H, Xu Y, Xu Y: The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response. Metabolism 2017;68:20-30
  • 104. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013;341:569-573
  • 105. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013;83:308-315
  • 106. Wang IK, Wu YY, Yang YF, Ting IW, Lin CC, Yen TH, Chen JH, Wang CH, Huang CC, Lin HC: The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: A randomised, double-blind, placebo-controlled trial. Benef Microbes 2015;6:423-430
  • 107. Vaziri ND, Liu S-M, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, Kieffer DA, Adams SH, Martin RJ: High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS ONE 2014;9: 114881
  • 108. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012;81:300- 306

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.